Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326793 | 1.00 | KRAS (0.33) | KRASSOS1AAK1 | |
| SCHEMBL24246883 | 0.85 | KRAS (0.35) | KRASSOS1 | |
| SCHEMBL21398387 | 0.77 | RPS6KA3 (0.33) | AAK1 | |
| SCHEMBL21055153 | 0.76 | KRAS (0.32) | KRASSOS1 | |
| SCHEMBL25706405 | 0.75 | RPS6KA3 (0.33) | — | |
| SCHEMBL4327782 | 0.75 | PDE2A (0.35) | AAK1 | |
| SCHEMBL26036544 | 0.72 | RPS6KA3 (0.34) | — | |
| SCHEMBL28912968 | 0.72 | TDO2 (0.33) | — | |
| SCHEMBL25707554 | 0.70 | RPS6KA3 (0.31) | — | |
| SCHEMBL25628418 | 0.70 | KRAS (0.34) | KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| CN-116425742-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230096028-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
| CN-114901662-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-113727758-A | Bicyclic heterocyclic compounds and use thereof | 锐新医药公司 | 2021-11-30 | — | — | CN | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | KRAS 12/4885SOS1 1/4885AAK1 2504/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | KRAS 14/4885SOS1 2/4885AAK1 2663/4885 |
| US-20230096028-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | SOST, SOS1, IQGAP1 | KRAS 11/4885SOS1 2/4885AAK1 3262/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | KRAS 14/4885SOS1 2/4885AAK1 2663/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | KRAS 14/4885SOS1 2/4885AAK1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.